NSAIDS for Cancer Therapy

Last Modified: May 13, 2007


Dear OncoLink "Ask The Experts,"

My wheaten terrier (11 yrs old) was diagnosed with TCC yesterday. She is prescribed Deramaxx. Is there any better treatment? Is this the same as Piroxicam?


Lili Duda, VMD, Section Editor of the OncoLink Veterinary Oncology Menu, responds:

Piroxicam, an NSAID, is a non-selective Cox-1 and Cox-2 inhibitor and has anti-cancer effects for both transitional cell carcinoma and squamous cell carcinoma in dogs, which is supported by the veterinary literature. Since those papers, veterinarians have prescribed other NSAIDS such as Deramaxx, in lieu of Piroxicam, because these newer selective Cox-2 inhibitors are associated with lower rates of side-effects, such as GI ulceration and upset. It is assumed (but not known) that the anti-tumor effects are due to the Cox-2 inhibition, so it is also assumed that cox-2 selective NSAIDs should work as well as piroxicam.

However, this remains to be supported in the veterinary literature. Chemotherapy is currently recommended as first-line treatment for canine transitional cell carcinoma, but Piroxicam (or possibly other NSAIDS) remains a reasonable palliative option. Please see our previously answered questions for more information on TCC treatment.


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

NSAID Use Linked to Reduced Risk of Skin Cancer

May 30, 2012

Lower risk of squamous cell carcinoma, malignant melanoma; notably in long-term, high-intensity use

Agent Orange Tied to MGUS in Vietnam Vets

Nov 29, 2015

Exposed veterans have higher rates of monoclonal gammopathy of undetermined significance

Nicotine Dependence Underdiagnosed in U.S. Vets

Oct 20, 2011

Vets without diagnosis less likely to be diagnosed and treated